Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

110P - Patient preferences for adjuvant endocrine treatment of high-risk HR+/HER2- breast cancer: an adaptive choice-based conjoint analysis study from Germany

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Achim Woeckel

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101219-101219. 10.1016/esmoop/esmoop101219

Authors

A. Woeckel1, T. Park-Simon2, A. Korfel3, K. Raab3, H. Silberzahn3, H. Tesch4

Author affiliations

  • 1 UKW - University Hospital Würzburg, Würzburg/DE
  • 2 MHH - Medizinische Hochschule Hannover, Hannover/DE
  • 3 Eli Lilly and Company, Bad Homburg/DE
  • 4 Zentrum für Hämatologie und Onkologie Bethanien, Frankfurt/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 110P

Background

Patient-centred care can improve disease-related outcomes and quality-of-life (QoL), but studies gauging patient preferences in early breast cancer (eBC) are limited. This study aimed at identifying preferences of patients (pts) with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) eBC related to adjuvant endocrine treatment (ET) characteristics.

Methods

Women with HR+/HER2- eBC with high-risk of relapse (defined by (neo)adjuvant chemotherapy pre-treatment) who were prescribed ET and diagnosed between 2009-2021 were recruited in Germany. Patient-relevant attributes for ET were identified by a stepwise multimodal approach [desk research, qualitative interviews (20 pts, 5 caregivers, and 12 physicians), quantitative survey (85 pts: 79 on ET, 6 planned), and cross-functional review]. A conjoint matrix was developed consisting of one attribute for ET goal (30% reduced risk of relapse), 4 attributes for QoL, and 5 attributes for side effects (Table), forming the basis of a subsequent adaptive choice-based conjoint survey.

Results

In the quantitative study, pts aged 49.4 years (mean) were included; among which 69.4% were still working. Relative assessment of ET attributes against each other revealed that achieving ET goal had the highest relevance, while avoiding side effects and maintaining QoL were less relevant. Most pts rated side effect avoidance, particularly diarrhoea, arthralgia, and nausea as the least relevant criterion for ET decision. Overall, 34.6% of pts have considered stopping ET while 6.4% have taken ≥ 1 break due to side effects.

Conclusions

ET goal attainment (30% reduced risk of relapse) was of greatest relative relevance to pts while side effect avoidance and QoL maintenance were less relevant highlighting the impact of relapse risk reduction on ET decisions in high-risk eBC. Table: 110P

ET attributes employed in the conjoint analysis

ET attribute Factors
Risk of tumour recurring in some way ET goal
Physical fitness and agility QoL
Mental/emotional stability QoL
Maintaining ability to work QoL
Participation in family life & leisure QoL
Diarrhea Side effects
Fatigue Side effects
Arthralgia Side effects
Loss of hair Side effects
Nausea Side effects
.

Editorial acknowledgement

Dr. Catherine Sirafim, an employee of Eli Lilly and Company, provided editorial assistance for this abstract.

Legal entity responsible for the study

Eli Lilly and Company.

Funding

Eli Lilly and Company.

Disclosure

A. Wöckel: Financial Interests, Personal, Other, Consulting honorarium: Amgen, AstraZeneca, Celgene, Eisai, Lilly, Novartis, Pfizer, Roche, Tesaro, Sirtex, MSD, Genomic Health, Pierre Fabre, Clovis, Organon, Seagen, Exact Sciences, Gilead, Dajiichi Sanko; Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Celgene, Eisai, Lilly, Novartis, Pfizer, Roche, Tesaro, Sirtex, MSD, Genomic Health, Pierre Fabre, Clovis, Organon, Seagen, Exact Sciences, Gilead, Dajiichi Sanko; Financial Interests, Personal, Other, Support for advanced trainings: Amgen, AstraZeneca, Celgene, Eisai, Lilly, Novartis, Pfizer, Roche, Tesaro, Sirtex, MSD, Genomic Health, Pierre Fabre, Clovis, Organon, Seagen, Exact Sciences, Gilead, Dajiichi Sanko. T. Park-Simon: Financial Interests, Personal and Institutional, Invited Speaker: Roche, GSK, AstraZeneca, Pfizer, Lilly, Daiichi-Synkyo, Seagen, Gilead, Eisai, MSD; Financial Interests, Personal and Institutional, Advisory Board: Roche, GSK, AstraZeneca, Pfizer, Lilly, Daiichi-Synkyo, Seagen, Gilead, Eisai, MSD; Financial Interests, Personal and Institutional, Principal Investigator: Roche, GSK, AstraZeneca, Pfizer, Lilly, Daiichi-Synkyo, Seagen, Gilead, Eisai, MSD. A. Korfel, K. Raab, H. Silberzahn: Financial Interests, Personal, Full or part-time Employment: Eli Lilly; Financial Interests, Personal, Stocks/Shares: Eli Lilly. H. Tesch: Financial Interests, Personal and Institutional, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer, Seagan, Daiichi, GSK, Exact Science, Vifor, Lilly, AstraZeneca, MSD; Financial Interests, Personal, Ownership Interest: VISION MED GmbH, Care and Coach GmbH, CHOP GmbH; Financial Interests, Personal, Funding: Lilly; Non-Financial Interests, Personal, Member: DGHO, ESMO, ASCO, Deutsche Gesellschaft für Senologie; Financial Interests, Personal, Other, Travel Expenses: GSK, Pfizer; Non-Financial Interests, Personal, Other, Travel Expenses: Deutsche Gesellschaft für Senologie.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.